Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice

Primary hyperoxaluria type I (PH I) is caused by deficiency of the liver-specific enzyme alanine-glyoxylate:aminotransferase (AGT). Many mutations are known to perturb AGT protein folding. Vitamin B6 (B6) is the only specific drug available for treatment. Although B6 has been used for >40 years,...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical journal of the American Society of Nephrology Vol. 9; no. 3; pp. 468 - 477
Main Authors:	Hoyer-Kuhn, Heike, Kohbrok, Sina, Volland, Ruth, Franklin, Jeremy, Hero, Barbara, Beck, Bodo B, Hoppe, Bernd
Format:	Journal Article
Language:	English
Published:	United States American Society of Nephrology 01-03-2014
Subjects:	Administration, Oral Adolescent Biomarkers - urine Child Female Genetic Predisposition to Disease Germany Heterozygote Homozygote Humans Hyperoxaluria, Primary - diagnosis Hyperoxaluria, Primary - drug therapy Hyperoxaluria, Primary - genetics Hyperoxaluria, Primary - urine Male Mutation Original Oxalic Acid - urine Phenotype Prospective Studies Time Factors Transaminases - genetics Treatment Outcome Vitamin B 6 - administration & dosage Vitamin B 6 - adverse effects Vitamin B 6 - blood Germany
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Primary hyperoxaluria type I (PH I) is caused by deficiency of the liver-specific enzyme alanine-glyoxylate:aminotransferase (AGT). Many mutations are known to perturb AGT protein folding. Vitamin B6 (B6) is the only specific drug available for treatment. Although B6 has been used for >40 years, controlled data on B6 efficacy are lacking. Therefore, this study investigated the absolute and relative change of urinary oxalate (Uox) excretion under increasing dosages of B6, the first prospective trial to do so. B6 response was studied in 12 patients (7 male patients) with genetically confirmed PH I (3 Gly170Arg homozygous, 5 compound Gly170Arg and/or Phe152Ile heterozygous, and 4 negative for Gly170Arg and/or Phe152Ile mutations) and noncompromised renal function. Efficacy was defined as a 30% relative reduction in Uox excretion. B6 was administered orally starting at 5 mg/kg body weight per day and given in increments of 5 mg/kg every 6 weeks, up to a final dosage of 20 mg/kg per day at week 24. Uox and serum B6 levels were measured every 6 weeks. Mean relative Uox reduction was 25.5%. Uox declined from 2.09±0.55 (mean±SD) at baseline to 1.52±0.60 mmol/1.73 m(2) per day (P=0.01) at week 24. Serum B6 levels increased from 22.5±8.7 to 1217±776 ng/ml (P<0.001). Six patients showed a ≥30% relative reduction of Uox at week 24. This first prospective trial confirmed B6 efficacy in 50% of patients (three of three homozygous, one of five heterozygous, and two of four patients negative for the Gly170Arg and/or Phe152Ile mutations). Interestingly, no complete biochemical remission was observed, even in the homozygous Gly170Arg study participants. Future trials are necessary to learn more about genotype-related B6 response and B6 metabolism.
Bibliography:	B.B.B. and B.H. contributed equally to this work.
ISSN:	1555-9041 1555-905X
DOI:	10.2215/CJN.06820613